MARKET

UBX

UBX

Unity Btech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.61
-0.22
-3.22%
Opening 14:00 01/22 EST
OPEN
6.82
PREV CLOSE
6.83
HIGH
6.86
LOW
6.61
VOLUME
369.62K
TURNOVER
--
52 WEEK HIGH
15.44
52 WEEK LOW
2.720
MARKET CAP
349.76M
P/E (TTM)
-3.5229
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
Zacks.com · 01/12 21:08
Are Options Traders Betting on a Big Move in Unity Biotechnology (UBX) Stock?
Investors need to pay close attention to Unity Biotechnology (CRMD) stock based on the movements in the options market lately.
Zacks · 01/12 15:44
CLSD, EBON, CGA and CNF among after-hours movers
Gainers: [[CLSD]] +9.9%. [[EBON]] +3.8%. [[ETM]] +3.6%. [[CVE]] +3.6%. [[UBX]] +3.6%.Losers: [[CGA]] -12.2%. [[CNF]] -12.1%. [[WBAI]] -10.7%. [[SCYX]] -9.2%. [[NRO]] -8.8%.
Seekingalpha · 12/31/2020 22:56
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 20)
Benzinga · 12/22/2020 12:45
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Benzinga · 12/22/2020 12:45
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
UNITY Biotechnology, Inc. ("UNITY") [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from December 1, 2020 through December 15, 2020, the Board of Directors (the "Board") grante...
GlobeNewswire · 12/16/2020 13:00
UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore O'Neill, M.B., to the Board of Directors
Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY's Board
GlobeNewswire · 12/14/2020 21:54
UNITY Biotechnology Announces Appointment of Clinical Development and Industry Veteran Gilmore ONeill, M.B., to the Board of Directors
Nathaniel E. David, Ph.D., to step down from Management Team, but will remain on UNITY’s Board Changes Reflect Strategic Focus on Clinical Development in Age-Related Diseases of the Eye and BrainSOUTH SAN FRANCISCO, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) ...
GlobeNewswire · 12/14/2020 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of UBX. Analyze the recent business situations of Unity Btech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average UBX stock price target is 5.67 with a high estimate of 12.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 125
Institutional Holdings: 19.87M
% Owned: 37.55%
Shares Outstanding: 52.91M
TypeInstitutionsShares
Increased
22
520.24K
New
43
-2.40M
Decreased
22
3.35M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.77%
Key Executives
Chairman/Director
Keith Leonard
President/Co-Founder/Director
Nathaniel David
Chief Executive Officer/Director
Anirvan Ghosh
Chief Financial Officer/Chief Accounting Officer
Lynne Sullivan
Chief Scientific Officer
Dan Marquess
General Counsel/Secretary
Tamara Tompkins
Executive Officer
Jamie Dananberg
Director
Mary Campbell
Director
Robert Nelsen
Director
Gilmore O Neill
Director
Luis Visoso
Independent Director
Paul Berns
Independent Director
Kristina Burow
Independent Director
Graham Cooper
Independent Director
David Lacey
Independent Director
Margo Roberts
Independent Director
Camille Samuels
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About UBX
Unity Biotechnology, Inc. is a clinical stage biotechnology company engaged in developing therapeutics to treat ageing related diseases. The Company develops therapeutics for age-associated diseases such as arthritis, vision loss, and cognitive decline. It develops a range of Senolytic medicines that eliminate senescent cells and stop the production of Senescence Associated Secretory Phenotype. Its pipelines of products that target cellular senescence are in its clinical development stage. Its lead products candidates include senolytic molecules, UBX0101 and UBX1967, designed for local treatment for the removal of accumulated senescent cells.UBX0101 is a drug candidate developed for musculoskeletal diseases targeting osteoarthritis. It is a inhibitor of the MDM2/p53 protein interaction that eliminates senescent cells. UBX1967 is targeted at ophthalmologic diseases. It is a senolytic small molecule inhibitor of specific members of the Bcl-2 family of apoptosis regulatory proteins.
More

Webull offers kinds of Unity Biotechnology Inc stock information, including NASDAQ:UBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading UBX stock methods without spending real money on the virtual paper trading platform.